Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Dinarello CA.

Blood. 2011 Apr 7;117(14):3720-32. doi: 10.1182/blood-2010-07-273417. Epub 2011 Feb 8. Review.

2.

Blocking interleukin-1β in acute and chronic autoinflammatory diseases.

Dinarello CA.

J Intern Med. 2011 Jan;269(1):16-28. doi: 10.1111/j.1365-2796.2010.02313.x. Review.

3.

Immune reconstitution following rabbit antithymocyte globulin.

Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, Ames S, Lerner S, Ebcioglu Z, Nair V, Dinavahi R, Sehgal V, Heeger P, Schroppel B, Murphy B.

Am J Transplant. 2010 Sep;10(9):2132-41. doi: 10.1111/j.1600-6143.2010.03210.x. Erratum in: Am J Transplant. 2010 Dec;10(12):2728.

4.

The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27.

Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK.

Nat Immunol. 2010 Sep;11(9):854-61. doi: 10.1038/ni.1912. Epub 2010 Aug 1.

5.

Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells.

Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ.

Nat Immunol. 2010 Sep;11(9):846-53. doi: 10.1038/ni.1915. Epub 2010 Aug 1.

6.

Immune intervention in children with type 1 diabetes.

Ludvigsson J; Linköping Diabetes Immune Intervention study group.

Curr Diab Rep. 2010 Oct;10(5):370-9. doi: 10.1007/s11892-010-0138-y.

PMID:
20668966
7.

A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG.

Mol Ther. 2010 Dec;18(12):2112-20. doi: 10.1038/mt.2010.146. Epub 2010 Jul 13.

8.

GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.

Chéramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R.

Clin Immunol. 2010 Oct;137(1):31-40. doi: 10.1016/j.clim.2010.06.001. Epub 2010 Jun 30.

PMID:
20580618
9.

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.

Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, Sorenson R, Luo J, Guo Z.

Endocrinology. 2010 Jul;151(7):3049-60. doi: 10.1210/en.2010-0068. Epub 2010 May 5.

PMID:
20444936
10.

Reversal of autoimmunity by boosting memory-like autoregulatory T cells.

Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, Yang Y, Medarova Z, Moore A, Santamaria P.

Immunity. 2010 Apr 23;32(4):568-80. doi: 10.1016/j.immuni.2010.03.015. Epub 2010 Apr 8.

11.

The role of immunomodulation therapy in autoimmune diabetes.

Ludvigsson J; Linköping Diabetes Immune Intervention Study Group.

J Diabetes Sci Technol. 2009 Mar 1;3(2):320-30. Review.

12.

Diagnosis and classification of diabetes mellitus.

American Diabetes Association.

Diabetes Care. 2010 Jan;33 Suppl 1:S62-9. doi: 10.2337/dc10-S062. No abstract available. Erratum in: Diabetes Care. 2010 Apr;33(4):e57.

13.

Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual beta cell function.

Dib SA, Gomes MB.

Diabetol Metab Syndr. 2009 Dec 4;1(1):25. doi: 10.1186/1758-5996-1-25.

14.

Prevention of type 1 diabetes.

Wherrett DK, Daneman D.

Endocrinol Metab Clin North Am. 2009 Dec;38(4):777-90. doi: 10.1016/j.ecl.2009.08.006. Review.

15.

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

N Engl J Med. 2009 Nov 26;361(22):2143-52. doi: 10.1056/NEJMoa0904452.

16.

Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P.

J Autoimmun. 2010 Jun;34(4):408-15. doi: 10.1016/j.jaut.2009.10.005.

17.

Cutting edge: normal regional lymph node enrichment of antigen-specific regulatory T cells with autoimmune disease-suppressive capacity.

Wheeler KM, Samy ET, Tung KS.

J Immunol. 2009 Dec 15;183(12):7635-8. doi: 10.4049/jimmunol.0804251.

18.

Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymph Nodes of NOD mice is associated with Islet Autoimmunity.

Regnault B, Osorio Y Fortea J, Miao D, Eisenbarth G, Melanitou E.

BMC Med Genomics. 2009 Oct 2;2:63. doi: 10.1186/1755-8794-2-63.

19.

Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.

Rewers M, Gottlieb P.

Diabetes Care. 2009 Oct;32(10):1769-82. doi: 10.2337/dc09-0374. No abstract available.

20.

Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population.

Siljander HT, Simell S, Hekkala A, Lähde J, Simell T, Vähäsalo P, Veijola R, Ilonen J, Simell O, Knip M.

Diabetes. 2009 Dec;58(12):2835-42. doi: 10.2337/db08-1305. Epub 2009 Sep 15.

Supplemental Content

Support Center